Charles W Rittershaus

Summary

Publications

  1. ncbi request reprint Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis
    C W Rittershaus
    AVANT Immunotherapeutics, Inc, Needham, MA 02494, USA
    Arterioscler Thromb Vasc Biol 20:2106-12. 2000
  2. ncbi request reprint Vaccines for cholesterol management
    Charles W Rittershaus
    AVANT Immunotherapeutics Inc, 119 Fourth Ave, Needham, Massachusetts 02494, USA
    World J Surg 31:690-4. 2007
  3. ncbi request reprint Co-administration of a CpG adjuvant (VaxImmune, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice
    Lawrence J Thomas
    AVANT Immunotherapeutics, Inc, Needham, Massachusetts 02494, USA
    Hum Vaccin 5:79-84. 2009
  4. ncbi request reprint Vaccines for the prevention of cardiovascular disease
    Una S Ryan
    AVANT Immunotherapeutics, Inc, 119 Fourth Avenue, Needham, MA 02494, USA
    Vascul Pharmacol 45:253-7. 2006
  5. ncbi request reprint Production of a complement inhibitor possessing sialyl Lewis X moieties by in vitro glycosylation technology
    Lawrence J Thomas
    AVANT Immunotherapeutics, 119 Fourth Ave, Needham, MA 02494, USA
    Glycobiology 14:883-93. 2004

Detail Information

Publications5

  1. ncbi request reprint Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis
    C W Rittershaus
    AVANT Immunotherapeutics, Inc, Needham, MA 02494, USA
    Arterioscler Thromb Vasc Biol 20:2106-12. 2000
    ..In addition, these studies suggest that vaccination against a self-antigen is a viable therapeutic strategy for disease management...
  2. ncbi request reprint Vaccines for cholesterol management
    Charles W Rittershaus
    AVANT Immunotherapeutics Inc, 119 Fourth Ave, Needham, Massachusetts 02494, USA
    World J Surg 31:690-4. 2007
    ..This review summarizes the published scientific work describing the various approaches that have been tried, their strengths and weaknesses, and where this field may go in the future...
  3. ncbi request reprint Co-administration of a CpG adjuvant (VaxImmune, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice
    Lawrence J Thomas
    AVANT Immunotherapeutics, Inc, Needham, Massachusetts 02494, USA
    Hum Vaccin 5:79-84. 2009
    ....
  4. ncbi request reprint Vaccines for the prevention of cardiovascular disease
    Una S Ryan
    AVANT Immunotherapeutics, Inc, 119 Fourth Avenue, Needham, MA 02494, USA
    Vascul Pharmacol 45:253-7. 2006
    ..This vaccine approach may offer the opportunity to address low HDL with a cost-effective semi-annual injection...
  5. ncbi request reprint Production of a complement inhibitor possessing sialyl Lewis X moieties by in vitro glycosylation technology
    Lawrence J Thomas
    AVANT Immunotherapeutics, 119 Fourth Ave, Needham, MA 02494, USA
    Glycobiology 14:883-93. 2004
    ..These results demonstrate that in vitro glycosylation of the sCR1 drug product reduces heterogeneity of the glycan profile, improves pharmacokinetics, and enhances carbohydrate-mediated binding to E-selectin...